A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion

Single dose safety and tolerability study: evaluate safety and tolerability of intravenous infusion nemonoxacin 25mg, 50mg, 125mg, 250mg, 500mg, 750mg, 1000mg and 1250mg.

Single dose pharmacokinetic (PK) study:evaluate PK profile of doses of 250mg, 500mg or 750mg intravenous infusion nemonoxacin .

Multiple dose study: evaluate PK profile of doses of 500mg, 650mg or 750mg intravenous infusion nemonoxacin after consecutive 10 days.

Inclusion criteria

• Healthy male or female, aged 18 ~45
• A male volunteer should be willing to use a double-barrier contraception until the study is completed, and should not make his partner pregnant during the study and within 3 months after completing the study
• Volunteers who have never used any tobacco or nicotine-containing product within three months before use of the investigational product
• Volunteers who are willing to abstain from caffeine- or xanthine- containing drinks or food within 24h before being enrolled in the study and throughout the study,such as coffee and tea,chocolate,alcohol, grapefruit juice,orange juice,etc.
• The body mass index (BMI) of the volunteer must be 19~24, and the weight of a male should be at least 50kg,and that of a female should be at least 45kg.
• Volunteers who are able to sign the informed consent form (ICF) of their own accord.

Exclusion criteria

• History of diabetes,or cardiovascular,hepatic or renal disease.
• Had surgery or trauma within 6 months prior to this study
• Alcohol or drug abuse
• HIV, HBV or HCV positive
• subject used any known hepatic enzyme inducer/hepatic enzyme inhibitor product within 30 days prior to the study
• Used any prescribed drug (including traditional chinese medicine) within 14 days prior to the study
• Donated 400ml of blood or plasma within 3 months prior to this study
• Have an abnormal laboratory examination value that exceeds the normal range by 10%
• Drug allergies
• Have cardiac disorders or have a family history of cardiac disorders
• Have abnormal 12-lead ECG during screening
• Pregnant or lactating
• Participated in any study within 3 months prior to this study
• according to the investigator's judgment, affect the safety or efficacy evaluation.